In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Growth

Set Alert for Growth

Pharma Sourcing And Procurement: The New Strategy Of Spend

Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise? In Vivo talks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value.  (3) Work fast – spend forward. (4) Reach out earn the business.

Business Strategies Growth BioPharmaceutical
Advertisement

Latest From Growth

Aptar's Focus On Digital Connectivity Presents New Drug Delivery Opportunities

Digital connectivity is the future of drug delivery, according to Aptar Pharma, which recently deepened its partnering commitment with digital therapeutics software developer Propeller Health. But it stresses that value is the key, and not connectivity for its own sake.

Growth Respiratory

‘Going Digital’ Is Changing Pharma’s Processes, People And Culture

Digital must become a core capability for pharma if it is to remain competitive. New technologies bring faster innovation cycles, but demand new kinds of expertise and partnerships that threaten traditional hierarchies and mindsets. The rewards, for pharma, are most likely to come from improved efficiency and stronger relationships with stakeholders, rather than from digital end-products.

Digital Health Artificial Intelligence

Vericel: Rebooting A Failing Business With Unloved Assets

Following the acquisition of cell therapy assets from Sanofi, which Sanofi had secured in its purchase of Genzyme, Aastrom Biosciences changed its name to Vericel, doubled down in cell therapy and relocated to Massachusetts. Since then it has seen its revenues grow 12% per year from just under $43 million in 2013 to just under $64 million in 2017. The target for 2020: drive revenues north of $100 million.

Business Strategies Growth

Record Breaking First Half For Start-Ups Raising Cash In Europe

The first half of 2018 appeared promising for the European biopharma sector, with multiple large investment funds promising cash to young, innovative companies in the region – a turnaround after years of life science firms suffering from a funding drought across Europe.

Growth Financing

Personalization And Digital Are Pushing IVDs Onto The Health Care High Ground

Investment in advanced in vitro diagnostics is increasing as the technologies themselves are becoming less esoteric and more easily "understood" by patients and providers alike. Are these technologies finally breaking through the glass ceiling to visibly assume their rightful place in health care delivery? 

EU In Vitro Diagnostics

Bayer’s US Playbook: The Smart Way To Top-Line Growth

The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

Leadership Growth
See All
UsernamePublicRestriction

Register